Coulter Partners provides leadership consultancy to Life Sciences, Health and Technology innovation businesses globally. We build teams that change the world and create a better future. Over 20 years we have delivered on 1000s of assignments across the USA, Canada, UK/Europe, and APAC, advising companies and investors on how to shape and hire their boards and leadership teams. We strongly impact value and growth. Our 110 experts operate uniquely as one global team. With our track record, AI, bespoke systems and wealth of data, we fuel the ability of investors, boards and executive teams to deliver value from innovation.
The Coulter Partners team is made up of 110 experts, working in 40 countries, holding 250,000 conversations with industry leaders each year. Together we channel data and learning to the benefit of our clients. We are a diverse group of experts with backgrounds ranging from science and technology, to the arts, finance, and more. Our reward system is designed to drive one-team behaviors and we work together seamlessly to combine industry experience and global insight with our passion for progress. Our team understands and is up to date with the challenges you face and the opportunities your business can maximize. This means we can find and develop exceptional individuals to drive you forward.
Our network is carefully curated and gives us access to leaders who can guide science, technology and innovation-driven companies through all stages of growth and evolution. Our executive search is an end-to-end process, underpinned by rigorous data and analytics from our dedicated Business Intelligence function and CP:Net™, our proprietary AI-driven candidate and company database. Our Board Advisory brings over two decades’ experience in building, advising and evolving boards for private and public companies. We understand what value a board can bring and how to evaluate its suitability for the stage of the business and the 3–5-year plan. We also provide leadership advisory at every step of the way. We have a network of mentors and advisors that bring the next level of insight to your organization, to build teams that change the world.
Executive search firm Coulter Partners recently helped Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, to secure the appointment of two diagnostic experts. Hayden Jeffreys joins the company as chief operating officer and Dr. Joanne Mason becomes vice president of biomarker discovery. The appointments are designed to further strengthen CEGX’s in-house expertise
Global life sciences recruiter Coulter Partners has made seven new appointments in the U.S., Switzerland, Germany and at its London headquarters. Joining the firm are Nona Footz, client partner; Samantha Simonnet, director on the U.S. West Coast; Jean Kim, associate director in New York; and Marie-Garance Leroy, senior consultant in Zurich. Also, Samantha Ng was appointed senior
Executive search firm Coulter Partners has placed Dr. Sonia Quaratino as chief medical officer of Kymab Group, a human monoclonal antibody biopharmaceutical company. She will manage the clinical development of the organization’s expanding therapeutic antibody portfolio. Dr. Quaratino is an immunologist and joins Kymab from Novartis, where she served as global clinical program leader – transitional clinical oncology, responsible for
Executive search firm Coulter Partners has opened a new office in Zurich and tapped Phillipp Buis to serve as executive director. This strategic expansion at the firm enhances Coulter Partners’ presence in this key Swiss life sciences market, while also strengthening its German, Austrian, and international networks further. Mr. Buis joins the Swiss based team at Coulter Partners to
LONDON, U.K., January 23, 2017 — Coulter Partners was delighted to partner with BONESUPPORT AB to secure the appointment of Björn Westberg as Chief Financial Officer and Director. A Scandinavian medical technology company, BONESUPPORT AB is an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery. Mr
LONDON, UK, January 8, 2017 – Coulter Partners was delighted to partner with global biotechnology company, Therachon to secure the appointment of Hans Schikan, Pharm.D., as a non- executive director to the Board of Directors. Therachon focuses on developing treatments for rare, genetic diseases that currently have no available treatments. Their lead pipeline candidate, TA-46, is
LONDON, U.K., January 4, 2017 — Coulter Partners was delighted to partner with Albumedix to secure the appointment of Dr. Giles Campion as Chief Medical Officer. Albumedix develops albumin-enabled therapeutics using its albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Using its products and technologies, Albumedix is advancing
LONDON, U.K., December 1, 2016 — Coulter Partners was delighted to partner once again with Medigene AG to secure the appointment of Dr. Thomas Taapken as Chief Financial Officer. Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The Company develops highly innovative, complementary treatment platforms to target various
LONDON, U.K., November 8, 2016 — Coulter Partners was delighted to partner once more with Erytech Pharma to secure the appointment of Dr. Alexander Scheer as Chief Scientific Officer. ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY) is a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. “Alexander brings a
News
Top hires for VC & PE portfolio companies Q1-2025
Evolution Italy: Life Science leaders gather for insightful discussions
Coulter Partners at BioCapital Europe 2025: Innovation and optimism reign
BioInnovation Institute Breakfast Seminar Health Tech Ecosystem – Copenhagen
BIA Gala Dinner 2025
Top hires for VC & PE portfolio companies Q4-2024
Top global hires for large-cap, mid-cap and public companies H2-2024
Coulter Partners attends AESC Global Conference: Inspire. Innovate. Impact.
Coulter Partners hosts inaugural annual partners meeting
Top hires for VC & PE portfolio companies Q3-2024
Packed house for Coulter Partners’ latest HealthTech Ecosystem breakfast
Coulter Partners runs Vitality 10K to raise money for Kith & Kids charity
Top hires for VC & PE portfolio companies Q2-2024
Top global hires for large-cap, mid-cap and public companies H1-2024
D, E & I: VIEWS FROM LEADERSHIP SERIES – Ankit Mahadevia, MD, Founder and Chair of Spero Therapeutics, and author of Quiet Leader, Loud Results
Top hires for VC & PE portfolio companies Q1-2024
D, E & I: VIEWS FROM LEADERSHIP SERIES – Lene Gerlach, Founder and Chair of Women in Life Science Denmark (WiLD), and Partner at Eir Ventures
D, E & I: VIEWS FROM LEADERSHIP SERIES – Yael Gruenbaum-Cohen, Partner at aMoon and Founder of WE@HealthTech
Top hires for VC & PE portfolio companies Q4-2023
Top global hires for large-cap, mid-cap and public companies H2-2023
Top hires for VC & PE portfolio companies Q3-2023
Top hires for VC & PE portfolio companies Q2-2023
Top global hires for large-cap, mid-cap and public companies H1-2023
Top hires for VC & PE portfolio companies Q1-2023
D, E & I: Views From Leadership Series – Charlotte Valeur, Founder of Institute Of Neurodiversity, ION
Top hires for VC & PE portfolio companies Q4-2022
Top global hires for large-cap, mid-cap and public companies H2-2022
Diversity, Equity, & Inclusion: Views From Leadership Series- Quita Highsmith, Vice President and Chief Diversity Officer at Genentech
Diversity, Equity & Inclusion: Views from Leadership-Tomoko Adachi
Diversity, Equity & Inclusion: Views from Leadership-Corinne Le Goff